School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eur J Ophthalmol. 2024 Jan;34(1):7-10. doi: 10.1177/11206721231199149. Epub 2023 Aug 30.
Diabetic macular edema (DME) is one of the leading causes of visual impairment in patients with diabetes. Multimodal imaging (MMI) has allowed a shift from DME diagnosis to prognosis. Although there are no accepted guidelines, MMI may also lead to treatment customization. Several study groups have tried to identify structural biomarkers that can predict treatment response and long-term visual prognosis. The purpose of this editorial is to review currently proposed optical coherence tomography (OCT) and optical coherence tomography angiography (OCT-A) biomarkers.
糖尿病性黄斑水肿（DME）是糖尿病患者视力损害的主要原因之一。多模态成像（MMI）已经实现了从 DME 诊断到预后的转变。尽管目前还没有公认的指南，但 MMI 也可能导致治疗的定制化。一些研究小组已经尝试确定可以预测治疗反应和长期视觉预后的结构生物标志物。本文的目的是回顾目前提出的光学相干断层扫描（OCT）和光学相干断层扫描血管造影（OCT-A）生物标志物。
